Ozempic Craze Has Spawned a Sketchy Black Market, FDA Warns

  • 📰 Gizmodo
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 51%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

The FDA has received adverse event reports from people using compounded semaglutide, which might not contain the same version of the popular obesity drug.

Semaglutide is a synthetic and longer-lasting version of glucagon-like peptide 1 developed by the company Novo Nordisk. GLP-1 and similar hormones help regulate our hunger and metabolism, often by affecting the release of other hormones such as insulin. As a result, GLP-1-basedhave been used for over a decade to help people manage their type 2 diabetes.

demand soon led to shortages of the drug. This demand has also led to shortages of Ozempic, the lower-dose brand of semaglutide approved for diabetes, as doctors began to prescribe it off-label for weight loss. Novo Nordisk has predictably disavowed the use of compounded semaglutide, stating that they do not sell the active ingredient to these pharmacies. On Tuesday, the FDA issued its own

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 556. in BR

Brasil Últimas Notícias, Brasil Manchetes